Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BRVE by emailGet an email when BRVE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BRVE, unsubscribe in one click. Privacy
📣 What BRVE Says Is Next
first half of 2027 · “Braveheart Bio has an open IND, and expects to initiate NOBLEHEART-HCM, a global Phase 3 trial in nHCM in the first half of 2027.”
Company press release, Sep 8, 2026 · SEC filing
first half of 2027 · “In addition, our program in non-obstructive HCM (“nHCM”) is advancing; we now have an active U.S. investigational new drug application (“IND”) and expect to initiate our NOBLEHEART-HCM Phase 3 study in the first half of 2027.” Second Quarter and Recent Business Highlights BHB-1893 Clinical Development”
Company press release, Sep 8, 2026 · SEC filing
second half of 2027 · “We continue to expect results from an interim analysis from LIONHEART-HCM in the second half of 2027.”
Company press release, Sep 8, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full BRVE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BRVE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.